Author information:
(1)From the Nordic Society of Gynecological Oncology and 
Rigshospitalet-Copenhagen University Hospital, Copenhagen (M.R.M.), Odense 
University Hospital (J.H.) and European Network for Gynacological Oncological 
Trial and Research Unit of General Practice, Institute of Public Health, 
University of Southern Denmark, Odense (R.D.C.) - all in Denmark; University of 
Arizona and Creighton University-Phoenix, Phoenix (B.J.M.), and Arizona Oncology 
Associates, Tuscon (B.J.M., J.B.) - all in Arizona; Princess Margaret 
Consortium, Princess Margaret Cancer Centre, University Health Network, 
University of Toronto, Toronto (A.M.O.), British Columbia Cancer Agency, 
Vancouver (A.V.T.), and McGill University-McGill University Health Centre, 
Montreal (L.G.) - all in Canada; Arbeitsgemeinschaft Gynäkologische Onkologie 
(AGO) and the University of Munich, Munich (S.M.), and Kliniken Essen Mitte, 
Essen (A.B.) - both in Germany; Grupo Español de Investigación en Cáncer de 
Ovario (GEICO) and Hospital Universitario La Paz (A.R.), and GEICO and M.D. 
Anderson Cancer Center Madrid (A.G.-M.), Madrid; French Investigator Group for 
Ovarian and Breast Cancer (GINECO) and Institut du Cancer de Montpellier, 
Montpellier (M.F.), and GINECO and Centre Antoine Lacassagne, Nice (P.F.) - both 
in France; National Cancer Research Institute and UCL Cancer Institute, 
University College London, London (J.A.L.); Multicenter Italian Trials in 
Ovarian Cancer/Mario Negri Gynecologic Oncology Group, Fondazione Istituto di 
Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan 
(D.L.); Belgium and Luxembourg Gynecological Oncology Group and University of 
Leuven, Leuven, Belgium (I.V.); Kaplan Medical Center, Rehovot, Israel 
(N.E.B.-B.); AGO-Austria and Medical University Innsbruck, Innsbruck, Austria 
(C.M.); Central and Eastern European Gynecologic Oncology Group and Uniwersytet 
Medyczny w Poznaniu, Poznan, Poland (R.M.); Stanford Comprehensive Cancer 
Institute, Stanford (J.S.B.), and Cedars-Sinai Medical Center, West Hollywood 
(B.J.R.) - both in California; Oslo University Hospital, Radiumhospitalet, Oslo 
(A.D.); Northside Hospital, Atlanta (B.B.); Universitetssjukhuset, Linköping, 
Sweden (P.R.); and Veristat, Southborough (J.P.B.), Tesaro, Waltham (S.A.), and 
Dana-Farber Cancer Institute, Boston (U.A.M.) - all in Massachusetts.